SEC Form 4 · accession 0001179110-18-002295
AbbVie Inc. · ABBV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Azita Saleki-Gerhardt
Officer — SVP, Operations
Period of report
Feb 15, 2018
Accepted (ET)
Feb 16, 2018 · 5:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001551152
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, $0.01 par valueF1 | Feb 15, 2018 | A | 7,080 | $0.00 | A | 91,879 | D | |
| Common stock, $0.01 par valueF2 | Feb 15, 2018 | A | 8,283 | $0.00 | A | 100,162 | D | |
| Common stock, $0.01 par valueF3 | Feb 15, 2018 | A | 7,170 | $0.00 | A | 107,332 | D | |
| Common stock, $0.01 par valueF4 | holding | — | — | — | 1,931 | I | Profit Sharing Trust | |
| Common stock, $0.01 par valueF5 | holding | — | — | — | 3,873 | I | By Spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F6 | $114.36 | Feb 15, 2018 | A | 23,160 | A | Feb 15, 2019 | Feb 14, 2028 | Common Stock | 23,160 | 23,160 | D |
Explanation of responses
- F1Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018.
- F2Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018.
- F3Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018.
- F4Balance in the AbbVie Savings Program as of February 15, 2018.
- F5The reporting person disclaims beneficial ownership of all securities held by her spouse.
- F6Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 7,720 on February 15, 2019, 7,720 on February 15, 2020, and 7,720 on February 15, 2021.